DLK1 (F7O3Q) Rabbit mAb #94845
- IHC
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 40-60 |
| Source/Isotype | Rabbit IgG |
Application Key:
- IHC-Immunohistochemistry
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:400 - 1:1600 |
| Flow Cytometry (Fixed/Permeabilized) | 1:200 - 1:800 |
| Flow Cytometry (Live) | 1:1800 - 1:7200 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Humans and rodents express multiple isoforms of DLK1, which are either membrane bound or contain an ADAM17/TACE cleavage site for release of the soluble ectodomain (8). As high DLK1 expression is pro-oncongenic in some contexts, differential isoform expression may promote cancer cell survival, with both the ectodomain and intracellular domain having distinct functions (9). Under hypoxic conditions, HIF proteins induce ADAM17/TACE cleavage and internalization of the DLK1 intracellular domain, which localizes to the nucleus and alters Akt and p53 signaling cascades in glioma (10). Hypoxia increases DLK1 expression, and phosphorylation of the DLK1 C-terminus at Tyr339 and Ser355 increases neuronal tumor sphere growth (11). Nuclear DLK1 directly interacts with tumor supressor NCoR1, correlating with poor prognosis in non small cell lung cancer (NSCLC) (12). DLK1 has emereged as a target for novel antibody drug conjugates (ADCs) in neuroblastoma and adrenocortical carcinoma (13,14).
- Laborda, J. et al. (1993) J Biol Chem 268, 3817-20.
- Smas, C.M. and Sul, H.S. (1993) Cell 73, 725-34.
- Kobayashi, S. et al. (2000) Genes Cells 5, 1029-37.
- Moon, Y.S. et al. (2002) Mol Cell Biol 22, 5585-92.
- Smas, C.M. et al. (1997) Mol Cell Biol 17, 977-88.
- Mei, B. et al. (2002) Biochem J 364, 137-44.
- Wang, Y. et al. (2006) J Nutr 136, 2953-6.
- Grassi, E.S. and Pietras, A. (2022) J Histochem Cytochem 70, 17-28.
- Pittaway, J.F.H. et al. (2021) Endocr Relat Cancer 28, R271-R287.
- Grassi, E.S. et al. (2020) Oncogene 39, 4028-4044.
- Kim, Y. et al. (2009) Cancer Res 69, 9271-80.
- Tan, J. et al. (2019) Biosci Rep 39, BSR20192362. doi: 10.1042/BSR20192362.
- Hamilton, A.K. et al. (2024) Cancer Cell 42, 1970-1982.e7.
- Sun, N.Y. et al. (2024) bioRxiv , 0.09.617077. doi: 10.1101/2024.10.09.617077.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.